Journal
MOLECULAR GENETICS AND METABOLISM
Volume 134, Issue 1-2, Pages 117-131Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ymgme.2021.07.006
Keywords
Fabry disease; Gene therapy; Gene editing; Lysosomal storage disease
Funding
- Faculty of Medicine Webster Family Fund for research in immunology or genetics from Dalhousie University
- Natural Sciences and Engineering Research Council of Canada (NSERC)/Collaborative Health Research Projects (CHRP) grant [433339]
- Midwest Athletes Against Childhood Cancer, Inc. (MACC Fund)
Ask authors/readers for more resources
Gene therapy has been increasingly used to treat various human diseases, including Fabry disease, a genetic disorder. Currently, there is no cure for Fabry disease, but emerging technologies like gene therapy hold promise for providing effective treatments.
Gene therapy is the delivery of a therapeutic gene for endogenous cellular expression with the goal of rescuing a disease phenotype. It has been used to treat an increasing number of human diseases with many strategies proving safe and efficacious in clinical trials. Gene delivery may be viral or non-viral, performed in vivo or ex vivo , and relies on gene integration or transient expression; all of these techniques have been applied to the treatment of Fabry disease. Fabry disease is a genetic disorder of the alpha-galactosidase A gene, GLA , that causes an accumulation of glycosphingolipids in cells leading to cardiac, renal and cerebrovascular damage and eventually death. Currently, there are no curative treatments available, and the therapies that are used have significant drawbacks. These treatment concerns have led to the advent of gene therapies for Fabry disease. The first Fabry patients to receive gene therapy were treated with recombinant lentivirus targeting their hematopoietic stem/progenitor cells. Adeno-associated virus treatments have also begun. Alternatively, the field of gene-editing is a new and rapidly growing field. Gene-editing has been used to repair disease-causing mutations or insert genes into cellular DNA. These techniques have the potential to be applied to the treatment of Fabry disease provided the concerns of gene-editing technology, such as safety and efficiency, were addressed. This review focuses on the current state of gene therapy as it is being developed for Fabry disease, including progresses and challenges as well as an overview of gene-editing and how it may be applied to correct Fabry disease-causing mutations in the future . (c) 2021 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available